 | |
- close
- close
|
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
WIKI ANALYSIS
Infinity Pharmaceuticals Inc. (IPI) is a biopharmaceutical company whose mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions. The company has built a pipeline of product candidates for multiple cancer indications, all of which represent proprietary applications of its expertise in small molecule drug technologies.
On September 12, 2006, Infinity Pharmaceuticals Inc. (a private company) completed a reverse merger with Discovery Partners International, Inc.(DPI), a public company. Infinity Pharmaceuticals Inc. (IPI) was the surviving corporation in the merger. The ticker symbol for Infinity Pharmaceuticals Inc. is INFI which trades on the NASDAQ Global Market. Upon completion of the merger, former old Infinity owned approximately 69% of the combined company on a fully-diluted basis and former DPI owned approximately 31% of the combined company on a fully-diluted basis. Accordingly, for all purposes, including SEC reporting, the financial statements for periods prior to the merger reflect the historical results of Old Infinity, and not DPI, and financial statements for all subsequent periods reflect the results of the combined company.
Infinity is headquartered in Cambridge, Massachusetts. As of March 31, 2007, the company had 115 full-time employees, 93 of whom were engaged in research and development and 22 of whom were engaged in management, administration and finance.
References
| ||||||
|
|
